H. Juergens

1.3k total citations
28 papers, 907 citations indexed

About

H. Juergens is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, H. Juergens has authored 28 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in H. Juergens's work include Sarcoma Diagnosis and Treatment (14 papers), Cardiac tumors and thrombi (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). H. Juergens is often cited by papers focused on Sarcoma Diagnosis and Treatment (14 papers), Cardiac tumors and thrombi (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). H. Juergens collaborates with scholars based in Germany, Austria and United Kingdom. H. Juergens's co-authors include Michael Paulussen, A. Zoubek, Jeremy Whelan, Alan Craft, Ian Lewis, Jean Michon, Christine Juergens, Odile Oberlin, Claire Weston and Claudia Rössig and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

H. Juergens

27 papers receiving 871 citations

Peers

Countries citing papers authored by H. Juergens

Since Specialization

Citations

This map shows the geographic impact of H. Juergens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Juergens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Juergens more than expected).

Fields of papers citing papers by H. Juergens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Juergens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Juergens. The network helps show where H. Juergens may publish in the future.

Co-authorship network of co-authors of H. Juergens

This figure shows the co-authorship network connecting the top 25 collaborators of H. Juergens. A scholar is included among the top collaborators of H. Juergens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Juergens. H. Juergens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92 2018 ·SHILAP Revista de lepidopterología ·Jeremy Whelan, Allan Hackshaw, Anne McTiernan, R. J. Grimer, D. Spooner, Jessica Bate, Andreas Ranft, Michael Paulussen, H. Juergens, Alan Craft, Ian Lewis	19
2	Whole Lung Irradiation in Patients With Relapsed Ewing Sarcoma 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Sergiu Scobioala, Uta Dirksen, H. Juergens, Hans Theodor Eich	0
3	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). 2016 ·Journal of Clinical Oncology ·Uta Dirksen, Marie‐Cécile Le Deley, Bernadette Brennan, Ian Judson, Mark L. Bernstein, Richard Görlick, Neyssa Marina, Richard B. Womer, Nathalie Cozic, Nathalie Gaspar, Gwénaël Le Teuff, Perrine Marec‐Bérard, Andreas Faldum, Michael Paulussen, H. Juergens, Lars Hjorth, Keith Wheatley, Mark Krailo, Jeremy Whelan, Douglas S. Hawkins	14
4	THE ROLE OF MEGATHERAPY (MGT) AND STEM CELL TRANSPLANTATION (SCT) IN HIGH RISK EWING TUMORS (ET): MORE THAN 30 YEARS OF EBMT ACTIVITY 2014 ·mediaTUM (Technical University of Munich) ·Ruth Ladenstein, D Valteau-Couanet, Evgenia Glogova, H. Juergens, S. Burdach, Jean Michon, H. van den Berg, Ian Lewis, I. Yaniv, Christina Peters	1
5	OR10-5 Phase I study of figitumumab and pegvisomant in patients with advanced solid tumors 2012 ·Growth Hormone & IGF Research ·Paul Haluska, Uta Dirksen, Arkadiusz Z. Dudek, Petri Bono, Heikki Joensuu, H. Juergens, Barbara Sleight, (unknown)	1
6	Randomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of the Euro-EWING.99-R1 trial. 2011 ·Journal of Clinical Oncology ·O. Oberlin, M. Le Deley, Uta Dirksen, I J Lewis, Andreas Ranft, Jean Michon, Michael Paulussen, Jeremy Whelan, Ruth Ladenstein, Bernadette Brennan, (unknown), Valérie Laurence, Henk van den Berg, Lars Hjorth, (unknown), K. Wheatley, M. M. Van Glabbeke, Ian Judson, A. W. Craft, H. Juergens, (unknown)	10
7	Aetiology of childhood acute leukaemias: current status of knowledge 2008 ·Radiation Protection Dosimetry ·Claudia Rössig, H. Juergens	24
8	Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT 2008 ·Bone Marrow Transplantation ·Katja Masjosthusmann, Karoline Ehlert, Bodo R. Eing, Jodie L. Roth, Gabriele Koehler, H. Juergens, (unknown), Andreas H. Groll	15
9	Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial 2006 ·Pediatric Blood & Cancer ·Christine Juergens, Claire Weston, Ian Lewis, Jeremy Whelan, Michael Paulussen, Odile Oberlin, Jean Michon, A. Zoubek, H. Juergens, Alan Craft	201
10	Comparative expression analysis of Pax3 and Pax7 during mouse myogenesis 2005 ·The International Journal of Developmental Biology ·David Horst, (unknown), Consolato Sergi, Gregor Mikuz, H. Juergens, Thomas Braun, (unknown)	81
11	Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study¹ 2005 ·Alimentary Pharmacology & Therapeutics ·Joachim Labenz, David Armstrong, K. Lauritsen, Peter Katelaris, Stephan Schmidt, K Schütze, Grzegorz Wallner, H. Juergens, Harold G. Preiksaitis, (unknown), Emma Nauclér, John R. Adler, Stefan Eklund	54
12	A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study 2005 ·Alimentary Pharmacology & Therapeutics ·Joachim Labenz, David Armstrong, K. Lauritsen, Peter Katelaris, Stephan Schmidt, K Schütze, Grzegorz Wallner, H. Juergens, Harold G. Preiksaitis, (unknown), Emma Nauclér, Stefan Eklund	106
13	Ewing?s sarcoma and primitive neuroectodermal tumor of hand and forearm 2004 ·Journal of Cancer Research and Clinical Oncology ·W. Daecke, S. Ahrens, H. Juergens, (unknown), V. Ewerbeck, R. Kotz, Winfried Winkelmann, Ludger Bernd	16
14	High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing’s Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation 2003 ·Journal of Clinical Oncology ·Stefan Burdach, Almut Meyer‐Bahlburg, H.‐J. Laws, Roland Haase, (unknown), Bernd Metzner, Angela Wawer, R. Finke, U. Göbel, Johannes Haerting, H. Pape, Helmut Gadner, Juergen Dunst, H. Juergens	84
15	Efficacy and kinetics of bone marrow processing and enrichment of haematopoietic progenitor cells (HPC) by a large-volume apheresis procedure 1997 ·Bone Marrow Transplantation ·U. Cassens, (unknown), Henk Garritsen, Reinhard Kelsch, Helmut Ostermann, Joachim Kienast, M. G. Kiehl, Thomas Buechner, J. van de Loo, H. Juergens, Walter Sibrowski	12
16	Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood — follow up after 9 years 1996 ·European Journal of Pediatrics ·G. Janka‐Schaub, D. Harms, Ulrich Goebel, Ulrike Graubner, P. Gutjahr, R. Haas, H. Juergens, H. Spaar, K. Winkler, (unknown)	13
17	Improved Prognosis for Childhood Acute Lymphocytic Leukemia with Very High White Blood Cell Count (> 100/nl) with Rotation of Non-Cross-Resistant Drug Combinations 1990 ·Hämatologie und Bluttransfusion ·G. Janka‐Schaub, Ulrich Goebel, Ulrike Graubner, R. Haas, H. Juergens, H. Spaar, K. Winkler	2
18	Elimination of l-Asparaginase in Children Treated for AcuteLymphoblastic Leukemia 1989 ·Developmental Pharmacology and Therapeutics ·Martin Brueck, (unknown), (unknown), H. Juergens, Ulrich Goebel, V. Wahn	7
19	Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). 1981 ·PubMed ·H. Juergens, Cynthia Kosloff, Anita Nirenberg, (unknown), Huvos Ag, Gerald Rosen	14
20	Combination chemotherapy (T-6) in the multidisciplinary treatment of Ewing's sarcoma. 1981 ·PubMed ·Gerald Rosen, H. Juergens, Brenda Caparros, Anita Nirenberg, Huvos Ag, Marcove Rc	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact